Global Natural Killer (NK) Cell Therapeutics Market is expected to grow with the CAGR of 40.5% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Global natural killer (NK) cell therapeutics market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in global natural killer (NK) cell therapeutics market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.
Merck KGaA is the dominating player in the global natural killer (NK) cell therapeutics market. The other key players existing in the market are Kiadis Pharma, Cytovia Therapeutics, Nkarta, Inc., Fate Therapeutics, EMERcell, Glycostem, Phio Pharmaceuticals, Innate Pharma, Inc., INmuneBIO, Gamida Cell, Bellicum Phamaceuticals, Inc., Acepodia Inc., Affimed GmbH, multimmune GmbH, Bristol-Myers Squibb Company, Kleo Pharmaceuticals, iCell Gene Therapeutics, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., NantKwest among others.
Merck KGaA headquartered is in Darmstadt, Germany. The company is engaged in providing solutions in the field of healthcare, life science and performance materials with a passion for technology and love for science. The company has three business segments including life science, healthcare, performance materials, in which healthcare is the market focused segment. The company has wide product categories such as healthcare, life science, performance materials in which healthcare is the market focused category. The company has wide presence across Africa, Asia, Europe, Latin America, North America, Oceania. The company also has various subsidiary companies such as Sigma-Aldrich (OM) Ltd. (Greece), Merck Foundation gGmbH (Germany), Merck S.A. (Venezuela), iOnctura SA (Switzerland), Merck Ltd. (U.K), Fluka Chemical Corp. (U.S.), among others.
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is headquartered in New York, U.S. founded in the 1887. The company is engaged in discovery, development and delivery of transformational medicines in different areas involving oncology, immunoscience, cardiovascular and fibrosis. The company has wide pipeline product categories which are solid tumors, hematology, immunology, fibrotic diseases, cardiovascular, neuroscience in which solid tumors, hematology, immunology are the market focused categories. The company has presence across North America, Europe, and Asia-Pacific. The company has various subsidiaries such as Ability Biomedical (USA) Corp.(U.S.), Bristol-Myers Squibb Canada Co.(Canada), Bristol-Myers Squibb Argentina S. R. L.(Argentina), BMS Pharmaceuticals Germany Holdings , B.V.(Germany), BMS Spain Investments, Inc.(Spain) among others.
Glycostem headquartered in Oss, the Netherlands. The company is focused on the development of stem cells derived natural - killer cells as a medicinal asset in the fight against cancer. The company has three pipeline products oNKord, CAR-NK, TCR-NK, which all are market focused products. The company has presence in Europe.
Global Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027
Europe Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027
North America Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027
Asia-Pacific Natural Killer (NK) Cell Therapeutics Market – Industry Trends and Forecast to 2027